RNS & Investor News

2021

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2020

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2019

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2018

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2017

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2016

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2015

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2014

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2013

SkinBioTherapeutics plc shareholding

19 May 2021

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that its entire shareholding in SkinBioTherapeutics plc (AIM: SBTX) consisting of 36,138,569 ordinary shares representing 23.1% of SkinBioTherapeutics plc's total issued share capital, has been dematerialised and transferred to a nominee CREST account (Dowgate Wealth). OptiBiotix plc remains the beneficial owner of the transferred 36,138,569 ordinary shares.

There has been no change in the Company's overall beneficial holding of its SkinBioTherapeutics plc shareholding which in total consists of 36,138,569 representing 23.1% of SkinBioTherapeutics plc's total issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

OptiBiotix Health plc

www.optibiotix.com

Neil Davidson, Chairman

Contact via Walbrook below

Stephen O'Hara, Chief Executive

 
  

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti

 
  

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 
  

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.